Clinical Trial Update: A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating nasal PYY3-36 versus placebo for weight loss in obese adults; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• nasal PYY3-36 (peptide YY3-36)

Snippet

Sponsor: Nastech Pharmaceutical Company, Inc. | Conditions: Obesity | Phase 2 | Status: COMPLETED